Microbiome-derived metabolome as a potential predictor of response to cancer immunotherapy

Cancer immunotherapy with checkpoint blockade has become standard of care treatment for numerous cancer types. Despite this, robust predictive biomarkers are lacking. There is increasing evidence that the host microbiome is a predictor of immunotherapy response, although the optimal host microbiome...

Descripción completa

Detalles Bibliográficos
Autores principales: Malczewski, Agnieszka Beata, Navarro, Severine, Coward, Jermaine IG, Ketheesan, Natkunam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Hypothesis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604862/
https://www.ncbi.nlm.nih.gov/pubmed/33127655
http://dx.doi.org/10.1136/jitc-2020-001383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7604862/
https://www.ncbi.nlm.nih.gov/pubmed/33127655
http://dx.doi.org/10.1136/jitc-2020-001383

Ejemplares similares